Loading
Life sciences · Journal article
Basic & Clinical Cancer Research · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Prostate cancer (PCa) is the second most prevalent malignancy and a leading cause of can- cer-related mortality in males worldwide. Despite advancements in therapeutic strategies, such as radical prostatectomy, radiotherapy, androgen deprivation therapy (ADT), and chemotherapy, treatment outcomes for metastatic castration-resistant PCa (mCRPC) re- main suboptimal. The androgen receptor (AR) and its downstream signaling pathways play a critical role in PCa progression. Genetic aberrations such as AR amplification, TP53 and PTEN loss, and MYC oncogene activation further drive disease advancement. Although prostate-specific antigen (PSA)-based screening is widely used, its limited impact on sur- vival underscores the need for more reliable biomarkers. Emerging evidence indicates that non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs), act as key regulators of gene expression. These molecules influence PCa cell proliferation, apoptosis, invasion, and metastasis. Their dif- ferential and stage-specific expression patterns suggest strong potential as diagnostic and prognostic biomarkers, as well as therapeutic targets. This review summarizes recent ad- vancements in ncRNA research in PCa, providing insights into their mechanistic roles, clin- ical applications, and future directions in precision oncology.